Ann: June 2022 Quarterly Update and Appendix 4C, page-6

PTX-100 expands study on promising results in T-cell lymphoma patients Patients with T-cell lymphomas (TCL) are being steadily enrolled and treated in the expansion cohort under the leadership of Professor Miles Prince, AM. Prescient anticipates that recruitment remains on track for completion by the end of calendar 2022 and looks forward to sharing an interim update as the trial unfolds. PTX-200 study expands cohort after 4th complete remission In parallel, Prescient’s Phase 1b study of PTX-200 combined with chemotherapy (cytarabine) in patients with relapsed and refractory acute myeloid leukemia (AML) reported that another patient in the study has now had complete remission of their disease at the 45mg/m2 dose. An additional partial response was also previously reported. Four patients in the study have now reported complete remission of their disease. Principal Investigator, Professor Jeffery Lancet, at the H. Lee Moffitt Cancer Center in Florida, together with Prescient, believes a dose level of 45mg/m2 of PTX-200 is worth exploring as be the optimal biological dose for patients with this aggressive cancer. Prescient looks forward to providing an update on this cohort in the coming months. OmniCAR progress continues Although no results have been made public on the OmniCAR programs, the Company is pleased to report that steady progress has been made across its programs, including in vivo studies. Despite the necessary optimisations required in therapeutic development, Prescient is pleased to report that data is unfolding that confirms its belief that OmniCAR is a transformative platform that can yield truly differentiated cell therapies. The Company looks forward to updating the market on these developments whilst being sensitive to ongoing commercial disclosure limitations.

still amazes me even with these huge hints the price sits at 0.18 !
I look forward to resharing these posts in a years time when we are flying and all sat on tidy returns!